Sina Jasim1, Vera J Suman2, Camilo Jimenez3, Pamela Harris4, Kostandinos Sideras5,6, Jill K Burton5, Francis Paul Worden7, Richard J Auchus8, Keith C Bible9. 1. Department of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. 2. Division of Biomedical Statistics and Informatics, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. 3. University of Texas, MD Anderson Cancer Center, 1155 Pressler Street, Houston, TX, 77030, USA. 4. National Institute of Health (NIH/NCI), 9000 Rockville Pike, Bethesda, MD, 20892, USA. 5. Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. 6. Department of Gastroenterology and Hepatology, Erasmus University Medical Center, NA-0621s, Gravendijkwal 230, Rotterdam, 3015 CE, Netherlands. 7. Division of Medical Oncology, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, MI, 48109, USA. 8. Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine and Department of Pharmacology, University of Michigan, 1150 West Medical Center Drive, Ann Arbor, MI, 48109, USA. 9. Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. bible.keith@mayo.edu.
Abstract
INTRODUCTION: Pheochromocytomas and paragangliomas (Pheo/PGL) are rare, vascular, sometimes malignant endocrine tumors. Case reports indicate the activity of vascular endothelium growth factor receptor-targeted kinase inhibitors in these cancers. OBJECTIVES: To assess the antitumor activity and tolerability of pazopanib in progressive malignant Pheo/PGL. PATIENTS AND METHODS: This multicenter Phase II trial (MC107C) enrolled individuals ≥18 years old with disease progression ≤ 6 months prior to registration, Eastern Cooperative Oncology Group PS 0-2, and measurable disease (response evaluation criteria in solid tumors 1.0). Pazopanib was administered in 28-day cycles, with the regimen ultimately being as follows: cycle 1: 400 mg daily on days 1-14, cycle 2: 800 mg daily on days 1-14, and then cycle 2 + : 800 mg daily on all days. RESULTS: The study was halted due to poor accrual. Seven patients were enrolled (05/2011-11/2014). One patient withdrew consent prior to treatment, leaving six evaluable patients. Treatment was discontinued, due to the following reasons: disease progression (4); withdrawal (1); and grade 4 (Takotsubo) cardiomyopathy (1). The median number of cycles administered was 4 (range: 2-29, total: 49). Four patients had >1 dose reduction due to the following reasons: fatigue (1), abnormal liver tests (2), hypertension and (Takotsubo) cardiomyopathy (1), and headaches (1). Common severe (Common Terminology Criteria for Adverse Events v3.0 grades 3-5) toxicities were as follows: hypertension (3/6), (Takotsubo) cardiomyopathy (2/6), diarrhea (1/6), fatigue (1/6), headache (1/6), and hematuria (1/6). One confirmed partial response was observed in PGL (17%, duration 2.4 years); median progression-free survival and overall survival were 6.5 and 14.8 months, respectively. CONCLUSION: Pazopanib has activity in Pheo/PGL requiring more study; optimal alpha- and beta-blockade are imperative pre-therapy in patients with secretory tumors, as risk of hypertension and cardiomyopathy are potentially life threatening.
INTRODUCTION: Pheochromocytomas and paragangliomas (Pheo/PGL) are rare, vascular, sometimes malignant endocrine tumors. Case reports indicate the activity of vascular endothelium growth factor receptor-targeted kinase inhibitors in these cancers. OBJECTIVES: To assess the antitumor activity and tolerability of pazopanib in progressive malignant Pheo/PGL. PATIENTS AND METHODS: This multicenter Phase II trial (MC107C) enrolled individuals ≥18 years old with disease progression ≤ 6 months prior to registration, Eastern Cooperative Oncology Group PS 0-2, and measurable disease (response evaluation criteria in solid tumors 1.0). Pazopanib was administered in 28-day cycles, with the regimen ultimately being as follows: cycle 1: 400 mg daily on days 1-14, cycle 2: 800 mg daily on days 1-14, and then cycle 2 + : 800 mg daily on all days. RESULTS: The study was halted due to poor accrual. Seven patients were enrolled (05/2011-11/2014). One patient withdrew consent prior to treatment, leaving six evaluable patients. Treatment was discontinued, due to the following reasons: disease progression (4); withdrawal (1); and grade 4 (Takotsubo) cardiomyopathy (1). The median number of cycles administered was 4 (range: 2-29, total: 49). Four patients had >1 dose reduction due to the following reasons: fatigue (1), abnormal liver tests (2), hypertension and (Takotsubo) cardiomyopathy (1), and headaches (1). Common severe (Common Terminology Criteria for Adverse Events v3.0 grades 3-5) toxicities were as follows: hypertension (3/6), (Takotsubo) cardiomyopathy (2/6), diarrhea (1/6), fatigue (1/6), headache (1/6), and hematuria (1/6). One confirmed partial response was observed in PGL (17%, duration 2.4 years); median progression-free survival and overall survival were 6.5 and 14.8 months, respectively. CONCLUSION: Pazopanib has activity in Pheo/PGL requiring more study; optimal alpha- and beta-blockade are imperative pre-therapy in patients with secretory tumors, as risk of hypertension and cardiomyopathy are potentially life threatening.
Authors: Keith C Bible; Vera J Suman; Julian R Molina; Robert C Smallridge; William J Maples; Michael E Menefee; Joseph Rubin; Kostandinos Sideras; John C Morris; Bryan McIver; Jill K Burton; Kevin P Webster; Carolyn Bieber; Anne M Traynor; Patrick J Flynn; Boon Cher Goh; Hui Tang; Susan Percy Ivy; Charles Erlichman Journal: Lancet Oncol Date: 2010-09-17 Impact factor: 41.316
Authors: Q Liu; G Djuricin; E D Staren; P Gattuso; V E Gould; J Shen; T Saclarides; D B Rubin; R A Prinz Journal: Surgery Date: 1996-12 Impact factor: 3.982
Authors: Montserrat Ayala-Ramirez; Cecile N Chougnet; Mouhammed Amir Habra; J Lynn Palmer; Sophie Leboulleux; Maria E Cabanillas; Caroline Caramella; Pete Anderson; Abir Al Ghuzlan; Steven G Waguespack; Desirée Deandreis; Eric Baudin; Camilo Jimenez Journal: J Clin Endocrinol Metab Date: 2012-09-10 Impact factor: 5.958
Authors: Andreas Zielke; Martin Middeke; Sebastian Hoffmann; Mario Colombo-Benkmann; Peter Barth; Iyad Hassan; Annette Wunderlich; Lorenz C Hofbauer; Quan-Yang Duh Journal: Surgery Date: 2002-12 Impact factor: 3.982
Authors: Camilo Jimenez; Maria E Cabanillas; Libero Santarpia; Eric Jonasch; Karen L Kyle; Elizabeth A Lano; Surena F Matin; Rodolfo F Nunez; Nancy D Perrier; Alexandria Phan; Thereasa A Rich; Beejal Shah; Michelle D Williams; Steven G Waguespack Journal: J Clin Endocrinol Metab Date: 2008-11-18 Impact factor: 5.958
Authors: Graeme Eisenhofer; Stefan R Bornstein; Frederieke M Brouwers; Nai-Kong V Cheung; Patricia L Dahia; Ronald R de Krijger; Thomas J Giordano; Lloyd A Greene; David S Goldstein; Hendrik Lehnert; William M Manger; John M Maris; Hartmut P H Neumann; Karel Pacak; Barry L Shulkin; David I Smith; Arthur S Tischler; William F Young Journal: Endocr Relat Cancer Date: 2004-09 Impact factor: 5.678
Authors: Anthony M Joshua; Shereen Ezzat; Sylvia L Asa; Andrew Evans; Reuben Broom; Marc Freeman; Jennifer J Knox Journal: J Clin Endocrinol Metab Date: 2008-11-11 Impact factor: 5.958
Authors: Camilo Jimenez; Guofan Xu; Jeena Varghese; Paul H Graham; Matthew T Campbell; Yang Lu Journal: Curr Oncol Rep Date: 2022-01-21 Impact factor: 5.075